New antibody combo shows promise for Hard-to-Treat cancers
Disease control
Completed
This early-phase study tested a new antibody called HMBD-002, given alone or with pembrolizumab, in 48 adults with advanced solid tumors (like lung or breast cancer) that had stopped responding to standard treatments. The main goals were to check safety, find the best dose, and s…
Phase: PHASE1 • Sponsor: Hummingbird Bioscience • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC